Paper41245385
Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.
Lee C and 9 others. Ther Adv Gastroenterol, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update. Papers, record 41245385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41245385
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Trials5
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT01925417 | Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02299570 | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT02589847 | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03244644 | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3) | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT03931941 | Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS) | Derived from the trial | Yes | ClinicalTrials.gov |
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40277958 | The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. | Infect Dis Rep | 2025 | https://conductscience.org/library/papers/40277958 | PubMed |
| 2 | 38395525 | AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases. | Gastroenterology | 2024 | https://conductscience.org/library/papers/38395525 | PubMed |
| 3 | 29617739 | Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection. | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/29617739 | PubMed |
| 4 | 33995583 | Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection. | Ther Adv Gastroenterol | 2021 | https://conductscience.org/library/papers/33995583 | PubMed |
| 5 | 36287379 | Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection. | Drugs | 2022 | https://conductscience.org/library/papers/36287379 | PubMed |
| 6 | 36544075 | Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection. | Infect Dis Ther | 2023 | https://conductscience.org/library/papers/36544075 | PubMed |
| 7 | 39180326 | PUNCH CD3-OLS: A Phase 3 Prospective Observational Cohort Study to Evaluate the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA) in Adults With Recurrent Clostridioides difficile Infection. | Clin Infect Dis | 2025 | https://conductscience.org/library/papers/39180326 | PubMed |
| 8 | 40784972 | Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome. | Infect Dis Ther | 2025 | https://conductscience.org/library/papers/40784972 | PubMed |
| 9 | 26565008 | Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/26565008 | PubMed |
| 10 | 36882700 | The burden of CDI in the United States: a multifactorial challenge. | BMC Infect Dis | 2023 | https://conductscience.org/library/papers/36882700 | PubMed |
| 11 | 40177588 | Safety and Efficacy of Fecal Microbiota, Live-jslm, in Preventing Recurrent Clostridioides difficile Infection in Participants Who Were Mildly to Moderately Immunocompromised in the Phase 3 PUNCH CD3-OLS Study. | Open Forum Infect Dis | 2025 | https://conductscience.org/library/papers/40177588 | PubMed |
| 12 | 39862395 | Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OLS. | Inflamm Bowel Dis | 2025 | https://conductscience.org/library/papers/39862395 | PubMed |
| 13 | 23804381 | Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. | J Clin Microbiol | 2013 | https://conductscience.org/library/papers/23804381 | PubMed |
| 14 | 37333464 | Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials. | Ther Adv Gastroenterol | 2023 | https://conductscience.org/library/papers/37333464 | PubMed |
| 15 | 32242357 | Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32242357 | PubMed |
| 16 | 35279084 | Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. | BMC Infect Dis | 2022 | https://conductscience.org/library/papers/35279084 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42840322 | Evaluation of fecal microbiota, live (RBL) for the prevention of recurrent Clostridioides difficile infection: Canadian subgroup analysis of an open-label phase 3 study. | J Can Assoc Gastroenterol | 2026 | https://conductscience.org/library/papers/42840322 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41245385
GET https://conductscience.org/api/papers/v1/41245385/authors